Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POMEROL: Infliximab Escalation for Postoperative Crohn's Recurrence
NCT05072782Phase 4Unknown
- Sponsor
- GETAID
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in Crohn's disease, sponsored by GETAID. Status: unknown.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05072782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072782.